• Defence Therapeutics appointed Ryan Simms as chief operating officer, adding oversight of its radiopharmaceutical drug conjugate programs.
• Simms previously held leadership roles at Fusion Pharmaceuticals, overseeing chemistry, radiochemistry, clinical manufacturing, external partnerships across clinical-stage programs.
• Fusion Pharmaceuticals was acquired by AstraZeneca in 2024 for about USD 2 billion.
• His past roles include Abdera Therapeutics, CPDC, spanning CMC strategy, manufacturing, isotope supply, radiochemistry, technical operations.
• Management flagged near-term plans to pick a lead candidate, start preclinical work, build CMC and manufacturing to support clinical progression.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Defence Therapeutics Inc. published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.